Moberg Derma AB: Moberg Derma Obtains Approval For Treatment For Atopic Eczema And Dry Skin

Moberg Derma AB (publ.) (STO:MOB) today announced that CE mark has been granted for Kaprolac Skin Repair & Hydration, a product designed to treat atopic eczema and dry skin. This CE mark provides authorization to market and sell the product in the EU/EEA.

Kaprolac Skin Repair & Hydration is a new, steroid-free treatment option for eczema and dry skin, such as atopic eczema. Treatment of eczema is a field which has been dominated by older products, with few new launches over the past few years, and Kaprolac Skin Repair & Hydration has properties which meet significant needs in the treatment of atopic eczema.

"We are now looking forward to working together with partners and distributors to make this product available to patients. The benign safety profile makes this Kaprolac product an interesting alternative for patients who are affected by recurrent and protracted problems with eczema. In a comparative study, the product demonstrated a greater ability to reinforce the skin barrier and re-hydrate the skin than a topical pharmaceutical based on propylene glycol," comments Peter Wolpert, CEO of Moberg Derma.

About the product and atopic eczema

Kaprolac Skin Repair & Hydration is a steroid-free treatment for eczema, for topical use, which is designed to treat the most common discomforts such as thickened, dry, itchy and red skin. In clinical trials, treatment with Kaprolac Skin Repair & Hydration led to a statistically significant clinical improvement in atopic eczema, and also of the moisture and barrier abilities of the skin. No adverse events were noted.

It is estimated that atopic eczema affects 15-20% of all children and 2-3% of the adult population.

Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 10 June, 08:00 am.

Source:
Moberg Derma

View the Original article